Abstract:Parkinson's disease (PD) is a common neurodegenerative condition marked by the degeneration of dopaminergic neurons and the amassing of α-synuclein protein in Lewy bodies. Chaperone-mediated autophagy (CMA), a selective form of autophagy, has been implicated in the development of PD. Mutant GBA1, α-synuclein, UCHL1, VPS35, and LRRK2 are affected proteins in PD that impair the CMA process. CMA Dysfunction cause accumulation of PD-associated proteins such as α-synuclein and many other, including DJ-1, MEF2D, PARK7,etc resulting in mitochondrial dysfunctioning and apoptosis. The impact of gene mutations associated with PD on CMA has been observed, along with dysregulation of miRNAs targeting CMA components. Toxicant-induced PD models demonstrate that impaired CMA increases α-synuclein aggregates and neurotoxicity. Understanding the molecular mechanisms of CMA has identified potential therapeutic targets, including increasing LAMP2A levels. Several compounds and substances have shown promise in enhancing CMA and reducing α- synuclein aggregates, such as 6-aminonicotinamide, geldanamycin, metformin, and natural compounds like trehalose and caffeine. Pharmacological modulation of CMA, such as through retinoic acid derivatives, has demonstrated positive effects on reducing protein aggregates in neurodegenerative diseases. However, the specific effects of inhibiting CMA on macroautophagy remain uncertain. Overcoming challenges in studying CMA, such as developing suitable models and monitoring methods, is crucial for advancing our understanding of CMA's role in neurodegenerative diseases and developing effective therapeutic strategies. Overall, CMA emerges as a key player in the pathogenesis of PD, and targeting this selective autophagy pathway holds promise for developing novel therapies to combat neurodegenerative disorders.

Chaperone-Mediated Autophagy in Neurodegenerative Diseases: Molecular Mechanisms and Pharmacological Opportunities

Chaperone-mediated autophagy in neurodegenerative diseases: mechanisms and therapy

Chaperone-mediated autophagy: roles in neurodegeneration.

Targeting chaperone-mediated autophagy in neurodegenerative diseases: mechanisms and therapeutic potential

Chaperone-Mediated Autophagy in Neurodegenerative Diseases and Acute Neurological Insults in the Central Nervous System

Chaperone-mediated autophagy: Molecular mechanisms, biological functions, and diseases

Chaperone-Mediated Autophagy: A Potential Target for Metabolic Diseases

Chaperone-mediated Autophagy: Advances from Bench to Bedside

Targeting Chaperone-Mediated Autophagy for Disease Therapy

Chaperone-mediated autophagy in cancer: Advances from bench to bedside

Navigating the cellular pathways: Chaperone-mediated autophagy as a targeted approach for management of parkinson\'s disease

Chaperone-Mediated Autophagy and Mitochondrial Homeostasis in Parkinson’s Disease

Crosstalk Between Macroautophagy and Chaperone-Mediated Autophagy: Implications for the Treatment of Neurological Diseases

Impact of Chaperone-Mediated Autophagy in Brain Aging: Neurodegenerative Diseases and Glioblastoma

The coming of age of chaperone-mediated autophagy

Selective protein degradation through chaperone‐mediated autophagy: Implications for cellular homeostasis and disease (Review)

The Role of Chaperone-Mediated Autophagy in Tissue Homeostasis and Disease Pathogenesis

Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: A mechanism review

Harnessing Nanochaperone-Mediated Autophagy for Selective Clearance of Pathogenic Tau Protein in Alzheimer's Disease

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Regulation of Autophagy in Neurodegenerative Diseases: A Brief Review on Autophagy Therapy for Neurodegenerative Diseases